Last reviewed 2026-04-19 · How we verify

Visudyne

At a glance

Approved indications

• Choroidal retinal neovascularization
• Exudative age-related macular degeneration
• Ocular histoplasmosis syndrome
• Pathologic Myopia

Common side effects

No common side effects on file.

Key clinical trials

• Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study (Phase 1)
• The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy (NA)
• Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and T (Phase 2)
• A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic The (Phase 4)
• Efficacy of Combining Intravitreal Bevacizumab With Photodynamic Therapy Using Reduced Light Fluence Rate in Choroidal Neovascularization Secondary to Pathologic Myopia. (Phase 1)
• Multi-Center, Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants With Neovascular Age-Relat (Phase 3)
• Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD (Phase 1)
• A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Visudyne CI brief — competitive landscape report
• Visudyne updates RSS · CI watch RSS
• Bayer portfolio CI